RFP
DNLI icon

Root Financial Partners’s Denali Therapeutics DNLI Stock Holding History

Root Financial Partners’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-188
Closed -$3.61K – 1138
2026
Q1 		$3.61K Buy
188
+88
+88% +$1.75K ﹤0.01% 2073
2025
Q4 		$1.65K Buy
100
+30
+43% +$506 ﹤0.01% 2021
2025
Q3 		$1.02K Buy
+70
New +$1.01K ﹤0.01% 2054

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Root Financial Partners's DNLI Position: Q2 2026 in Review

Root Financial Partners sold out of Denali Therapeutics (DNLI) in Q2 2026, closing a stake of 188 shares — an estimated $3.61K sold.

Root Financial Partners first reported a position in DNLI in Q3 2025 and held it in 3 quarters. The position peaked at $3.61K in Q1 2026. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Root Financial Partners reported no remaining Denali Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Root Financial Partners sold 188 Denali Therapeutics shares in Q2 2026, an estimated $3.61K.
  • Root Financial Partners first reported a position in Denali Therapeutics in Q3 2025 and held it in 3 quarters.
  • Root Financial Partners's Denali Therapeutics position peaked at $3.61K in Q1 2026.
  • 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Root Financial Partners's 13F filing for Q2 2026, filed 29 Jul 2026.